Venture capital firm
Venrock portfolio
venrock.comVenrock is a venture capital firm based in Palo Alto, United States, founded in 1969. It has invested in 93 venture-backed companies across 150 funding rounds on VCMC, and led 52 of those rounds. 12 of them were in the last 12 months.
93
Venture-backed companies
in its portfolio on VCMC
150
Funding rounds
led 52
12
Last 12 months
rounds, Oct 2025 to Sep 2026
24
With a disclosed valuation
of 93 companies
$97.7B
Combined value of its private companies
the whole companies, not what Venrock owns
82 private companies Venrock has backed have a VCMC valuation; together they are worth $97.7B. That is the value of the whole companies, not what Venrock owns. Devoted Health is 18% of the total. 11 companies it backed have since been acquired and are not included. How VCMC values companies.
Values cover private companies only; public companies are not included.
Portfolio
Venrock's most valuable portfolio companies
The 10 most valuable private companies Venrock has backed, by VCMC's valuation. Values cover private companies only; public companies are not included.
- 1 Devoted Health Insurance - Agents, Carriers & Brokers, Eagan $18.0B range $11.5B – $20.8B Led at Seed, 2017
- 2 Lyra Health Psychologists & Counseling Services, Burlingame $6.6B range $974M – $9.9B Led at Series A, 2015
- 3 Dapper Labs Tech Companies, Vancouver $4.9B range $661M – $9.2B Joined at Growth, 2021
- 4 Pharmaceutical Products, Philadelphia $4.7B range $2.4B – $7.2B Joined at Growth, 2024
- 5 Aledade Health Care Services, Bethesda $4.1B range $1.2B – $5.6B Led at Series A, 2014
- 6 Tech Companies, New York $3.8B range $1.3B – $5.7B Led at Series A, 2020
- 7 Encoded Therapeutics Biotechnology, South San Francisco $3.6B range $2.3B – $6.8B Led at Series C, 2019
- 8 Nutritionists & Weight Loss Specialists, Covina $3.3B range $487M – $3.8B Led at Series A, 2017
- 9 Astranis Aerospace and Defence, San Francisco $3.2B range $2.4B – $4.3B Led at Series B, 2020
- 10 Mirador Biotechnology, San Diego $2.8B range $1.2B – $4.3B Joined at Series A, 2024
Portfolio
Full Venrock portfolio (93 companies)
93 companies. Load more shows the rest.
| # | Last round | History | Range | Trend | Grade | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Devoted Health Insurance - Agents, Carriers & Brokers · led at Seed, 2017 | Series F Nov 2025 $48M | $18.0B | $11.5B – $20.8B | $18.1B (+1%) | $2.0B | 0% | 2,371 | up | A | |
| 2 | Astranis Aerospace and Defence · led at Series B, 2020 | Series E May 2026 $300M | $3.2B | $2.4B – $4.3B | $3.7B (+16%) | $410M | 0% | 563 | up | A | |
| 3 | Dataminr Tech Companies · led at Series C, 2013 | Growth Equity Mar 2025 $85M | $1.0B | $512M – $1.6B | $951M (-6%) | $96.6M | 18% | 882 | up | B | |
| 4 | Aledade Health Care Services · led at Series A, 2014 | Debt Dec 2025 $500M | $4.1B | $1.2B – $5.6B | $3.9B (-4%) | $548M | 0% | 1,955 | up | C | |
| 5 | Element Biosciences Biotechnology · led at Series A, 2019 | Series E Jun 2026 $175M | $2.4B | $1.4B – $4.4B | $2.9B (+18%) | $315M | 0% | 448 | flat | B | |
| 6 | Lyra Health Psychologists & Counseling Services · led at Series A, 2015 | Series F Jan 2022 $235M | $6.6B | $974M – $9.9B | $6.3B (-4%) | $1.0B | 0% | 2,973 | up | D | |
| 7 | Mirador Biotechnology · since Series A, 2024 | Series B Sep 2025 $250M | $2.8B | $1.2B – $4.3B | $2.8B (0%) | $307M | 0% | 97 | up | C | |
| 8 | Dapper Labs Tech Companies · since Growth, 2021 | Growth Equity Sep 2021 $250M | $4.9B | $661M – $9.2B | $4.6B (-7%) | $752M | 30% | 190 | unknown | D | |
| 9 | Encoded Therapeutics Biotechnology · led at Series C, 2019 | Series F Sep 2026 $275M | $3.6B | $2.3B – $6.8B | $4.5B (+26%) | $492M | 0% | 192 | up | B | |
| 10 | Skyryse Aircraft Parts & Services · since Series B, 2021 | Series C Feb 2026 $300M | $1.4B | $1.0B – $1.7B | $1.5B (+7%) | $162M | 0% | 197 | flat | A | |
| 11 | Tubulis Pharmaceutical Products · led at Series C, 2025 | Series C Oct 2025 $358M | $2.7B | $1.8B – $3.1B | $2.7B (0%) | $326M | 0% | 77 | up | A | |
| 12 | Atom Computing Device Manufacturing · since Series A, 2021 | Growth Equity Jun 2026 $300M | $2.0B | $1.4B – $3.1B | $2.2B (+8%) | $194M | 0% | 150 | growing | B | |
| 13 | RefleXion Medical Supply Manufacturers · since Series A, 2014 | Growth Equity Nov 2023 $105M | $384M | $219M – $888M | $211M (-45%) | $98.8M | 97% | 123 | shrinking | C | |
| 14 | Altruist Investment Consultants & Financial Advisors · led at Series A, 2019 | Series F Apr 2025 $152M | $1.4B | $1.1B – $2.0B | $813M (-42%) | $225M | 97% | 327 | shrinking | A | |
| 15 | Salsify Tech Companies · since Series C, 2017 | Series F Apr 2022 $200M | $1.3B | $147M – $2.7B | $1.2B (-8%) | $286M | 14% | 587 | flat | D | |
| 16 | Tech Companies · since Growth, 2019 | Series E Jan 2022 $200M | $1.4B | $367M – $5.7B | $1.4B (-5%) | $575M | 71% | 56 | down | D | |
| 17 | Tech Companies · led at Series B, 2008 | Growth Equity Aug 2021 $90M | $902M | $63.5M – $1.5B | $902M (0%) | $104M | 0% | 250 | flat | D | |
| 18 | Translation Services · led at Series A, 2010 | Growth Equity Dec 2021 $160M | $1.5B | $87.1M – $3.2B | $1.5B (0%) | $189M | 0% | 320 | unknown | D | |
| 19 | Tech Companies · since Series C, 2014 | Growth Equity Jul 2020 $100M | $365M | $67.8M – $990M | $365M (0%) | $100M | 52% | 248 | flat | D | |
| 20 | Tech Companies · since Series B, 2022 | Series B Aug 2022 $40M | $171M | $32.0M – $446M | $147M (-15%) | $44.5M | 46% | 123 | up | D | |
| 21 | Tech Companies · led at Seed, 2024 | Series A Nov 2025 $35M | $388M | $160M – $580M | $409M (+5%) | $57.2M | 0% | 72 | growing | C | |
| 22 | Tech Companies · since Series C, 2014 | Other Jun 2019 $5.9M | $118M | $14.3M – $302M | $118M (0%) | $31.2M | 35% | 89 | flat | D | |
| 23 | Tech Companies · since Series A, 2026 | Series A Jul 2026 $27M | $172M | $103M – $372M | $262M (+53%) | $36.7M | 0% | 87 | growing | C | |
| 24 | Tech Companies · since Series A, 2022 | Series A Apr 2022 $24M | $146M | $11.0M – $253M | $144M (-1%) | $25.5M | 0% | 37 | up | D | |
| 25 | Tech Companies · since Series D, 2008 | Other Jun 2012 $14M | $160M | $10.9M – $277M | $160M (0%) | $23.8M | 9% | 206 | flat | D | |
| 26 | Tech Companies · since Growth, 2024 | Growth Equity Oct 2024 $25M | $167M | $98.0M – $330M | $93.1M (-44%) | $27.5M | 97% | 66 | shrinking | C | |
| 27 | Tech Companies · led at Series A, 2025 | Series A Dec 2025 $17M | $150M | $63.1M – $229M | $161M (+8%) | $22.6M | 0% | 39 | growing | C | |
| 28 | Professional & Management Training · led at Series A, 2012 | Series A Apr 2012 $8.0M | $5.60M | $2.11M – $35.2M | $5.60M (0%) | $7.55M | 97% | 259 | down | D | |
| 29 | Tech Companies · led at Seed, 2022 | Acquisition Oct 2025 | $13.1M acquired 2025 | $5.61M – $54.1M | – | – | 97% | 19 | down | D | |
| 30 | Tech Companies · led at Seed, 2023 | Seed May 2023 $5.0M | $66.7M | $4.96M – $101M | $66.7M (0%) | $12.0M | 0% | 3 | unknown | D | |
| 31 | Tech Companies · led at Seed, 2013 | Seed Sep 2013 $2.0M | $3.11M | $0.53M – $17.6M | $3.11M (0%) | $2.88M | 65% | – | flat | D | |
| 32 | Tech Companies · led at Seed, 2020 | Seed Dec 2020 | $5.60M | $1.10M – $20.0M | $5.81M (+4%) | $7.92M | 73% | 3 | shrinking | D | |
| 33 | Business and HR Consulting · led at Seed, 2013 | Series C May 2015 $500M | $1.3B | $391M – $4.3B | $1.3B (0%) | $644M | 70% | 227 | flat | D | |
| 34 | Pharmaceutical Products · led at Series B, 2020 | Acquisition Dec 2023 $4.10B | $2.4B acquired 2023 | $1.2B – $3.4B | – | – | 0% | 96 | up | B | |
| 35 | Biotechnology · led at Series D, 2026 | Series D May 2026 $220M | $2.2B | $1.4B – $3.6B | $2.5B (+17%) | $303M | 0% | 65 | growing | B | |
| 36 | Tech Companies · led at Series A, 2020 | Series D May 2025 $93M | $3.8B | $1.3B – $5.7B | $3.8B (0%) | $283M | 0% | 4,493 | growing | C | |
| 37 | Nutritionists & Weight Loss Specialists · led at Series A, 2017 | Series E Apr 2021 $133M | $3.3B | $487M – $3.8B | $3.2B (-4%) | $408M | 0% | 902 | up | D | |
| 38 | Biotechnology · led at Series A, 2024 | Acquisition May 2026 $2.20B | $4.2B acquired 2026 | $1.4B – $6.5B | – | – | 0% | 45 | up | C | |
| 39 | Health Care Services · since Series A, 2013 | Growth Equity Sep 2020 $175M | $813M | $127M – $1.9B | $803M (-1%) | $178M | 43% | 1,734 | flat | D | |
| 40 | Pharmaceutical Products · led at Series D, 2026 | Series D Feb 2026 $130M | $1.9B | $1.1B – $2.9B | $2.1B (+9%) | $226M | 0% | 65 | growing | B | |
| 41 | Pharmaceutical Products · since Series A, 2025 | Series B Aug 2026 $115M | $898M | $540M – $1.9B | $1.2B (+37%) | $136M | 0% | 18 | unknown | C | |
| 42 | Pharmaceutical Products · since Growth, 2024 | Growth Equity Aug 2024 $275M | $4.7B | $2.4B – $7.2B | $4.7B (0%) | $426M | 0% | 85 | growing | B | |
| 43 | Pharmaceutical Products · since Series B, 2024 | Series C Apr 2026 $75M | $703M | $420M – $1.2B | $750M (+7%) | $99.5M | 25% | 67 | flat | B | |
| 44 | Biotechnology · led at Series B, 2025 | Series B Apr 2025 $155M | $1.5B | $663M – $2.1B | $1.5B (0%) | $161M | 0% | 84 | up | B | |
| 45 | Health Care Services · led at Seed, 2013 | Series D Jul 2020 $75M | $970M | $89.8M – $1.4B | $927M (-4%) | $133M | 0% | 1,331 | up | D | |
| 46 | Tech Companies · since Series B, 2020 | Series E Oct 2026 $90M | $1.1B | $793M – $2.1B | $1.5B (+29%) | $161M | 0% | 408 | up | B | |
| 47 | Biotechnology · led at Series B, 2017 | Series D Dec 2019 $125M | $164M | $88.2M – $427M | $164M (0%) | $179M | 97% | – | shrinking | C | |
| 48 | Aerospace and Defence · since Series B, 2021 | Series B Oct 2021 $200M | $324M | $131M – $1.8B | $321M (-1%) | $293M | 91% | 56 | down | D | |
| 49 | Biotechnology · since Series C, 2024 | Series C Jun 2024 $90M | $369M | $194M – $937M | $175M (-53%) | $105M | 97% | 32 | shrinking | C | |
| 50 | Pharmaceutical Products · led at Series A, 2025 | Series A Jan 2025 $180M | $1.8B | $410M – $2.7B | $1.8B (0%) | $252M | 0% | 7 | unknown | C |
Valuation: VCMC's valuation with its range, from a low to a high scenario; a company with no valuation shows a dash, one acquired after its last round its last value as a private company.
Activity
How Venrock invests: stages, industries and countries
Most of its rounds are Series C and later (41%). Its companies span 26 industries, most in Tech Companies, Biotechnology and Pharmaceutical Products, across 7 countries.
Rounds by stage
- Seed 14
- Series A 38
- Series B 36
- Series C and later 62
Investments by industry
- Tech Companies 38
- Biotechnology 12
- Pharmaceutical Products 10
- Health Care Services 4
- Aerospace and Defence 3
- Insurance - Agents, Carriers & Brokers 3
- Medical Supply Manufacturers 3
- Investment Consultants & Financial Advisors 2
Investments by country
- United States 85
- Israel 2
- United Kingdom 2
- Canada 1
- Denmark 1
- Germany 1
Recent rounds
Venrock's latest investments
Venrock's most recent funding rounds, newest first. 12 rounds in the last 12 months.
- Series E $90M 14 Oct 2026
- Encoded Therapeutics Series F $275M 9 Sep 2026
- Series A, led $20M 13 Aug 2026
- Series B $115M 5 Aug 2026
- Series A $27M 14 Jul 2026
- Series D, led $220M 6 May 2026
- Series C $75M 14 Apr 2026
- Series D, led $130M 5 Feb 2026
- Series B $60M 2 Feb 2026
- Series A, led $17M 1 Dec 2025
Co-investors
Venrock's top co-investors
The investors that most often join the same rounds as Venrock. Andreessen Horowitz leads, with 13 rounds together.
- Andreessen Horowitz 13 rounds together
- 9 rounds together
- 9 rounds together
- 9 rounds together
- ARCH Venture Partners 8 rounds together
- Bain Capital Ventures 8 rounds together
- 7 rounds together
- Greylock Partners 7 rounds together
- 7 rounds together
- 6 rounds together
About
About Venrock
Venrock Management, LLC is an American venture capital firm that provides investment management and advisory services to portfolio companies across sectors such as healthcare, technology, consumer, financial services, life sciences, cybersecurity, and aerospace. The firm operates two distinct investment programs: a traditional venture capital program for early-stage companies and a later-stage healthcare program focused on small capitalization public companies and late-stage private healthcare firms. Venrock also offers strategic partnerships and long-term growth support to its portfolio companies.
Description from Veridion's company data.
- Founded
- 1969
- Based in
- Palo Alto, United States
- Team
- 70 people, -8% in a year
- Type
- Venture capital firm
Focus markets
- Healthcare
- Technology
- Consumer
- Financial Services
- Life Sciences
- Cybersecurity
- Aerospace
What Venrock offers
- Venture Capital Investment Management
- Healthcare Venture Capital Investment
- Technology Venture Capital Investment
- Later-Stage Healthcare Investment
- Portfolio Company Strategic Advisory Services
- Venture Capital Advisory Services
- Long-Term Growth Partnership Services
- Healthcare Portfolio Company Development
Questions
Venrock: frequently asked questions
How many companies has Venrock invested in?
93 venture-backed companies on VCMC, across 150 funding rounds.
What are Venrock's most valuable private companies?
Devoted Health ($18.0B), Lyra Health ($6.6B), Dapper Labs ($4.9B), by VCMC's valuation.
What was Venrock's latest investment?
Suki, a Series E round in Oct 2026 of $90M.
Which stages does Venrock invest in?
Venrock invests most often at Series C and later (62 rounds), followed by Series A (38) and Series B (36). It has also joined 14 seed rounds.
What is Venrock's portfolio worth?
Its private companies with a VCMC valuation are worth $97.7B together. That is the sum of the companies' values, not what Venrock owns.
Who does Venrock invest alongside?
Andreessen Horowitz (13 rounds), Foresite Capital (9 rounds), RA Capital (9 rounds).